CSIMarket Company Name, Ticker, Industry, else..
 
Ernexa Therapeutics Inc   (NASDAQ: ERNA)
 
Price: $4.2170 $0.20 4.900%
Day's High: $4.419899940490723 Week Perf: -2.16 %
Day's Low: $ 4.03 30 Day Perf: -4.59 %
Volume (M): 15,301 52 Wk High: $ 71.50
Volume (M$): $ 0 52 Wk Avg: $16.78
Open: $4.03 52 Wk Low: $3.18



 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 1
 Employees 5
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Eterna Therapeutics Inc, also known as Eterna, is a biotechnology company that is focused on the development of mRNA-based therapies. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Eterna is driven by a mission to advance the field of RNA therapeutics, with a focus on leveraging the power of messenger RNA (mRNA) to develop precise and effective treatments for a range of diseases. The company's proprietary mRNA platform is designed to enable the rapid development of targeted, safe, and potent therapies, using a modular approach that can be easily adapted to specific therapeutic targets.

Eterna's approach to mRNA therapy is distinguished by its use of "pure" mRNA, which is unmodified and free from any chemical modifications that could potentially limit its therapeutic potential. This approach allows for the creation of highly precise mRNA sequences that can be tailored to the specific needs of each patient.

Eterna has a number of ongoing research programs in a range of therapeutic areas, including oncology, immunology, and rare genetic disorders. Its lead product candidate is currently in preclinical development, aimed at the treatment of solid tumors.

The company has built a strong team of experts in RNA biology, drug development, and clinical research, and has collaborated with a number of leading academic and research institutions to advance its pipeline of mRNA therapies.

Eterna is supported by a group of prominent investors, including Fidelity, Omega Funds, and Cormorant Asset Management, among others. The company has raised approximately $70 million in total funding to date.


   Company Address: 1035 Cambridge Street, Suite 18A Cambridge 2141 MA
   Company Phone Number: 798-6700   Stock Exchange / Ticker: NASDAQ ERNA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EBS   -3.05%    
OPK   -4.97%    
PFE   -4.46%    
RARE   -4.24%    
RCUS   -16.64%    
SIGA   -5.57%    
• View Complete Report
   



Shares

Ernexa Therapeutics Reinvents Itself: New Funding and Strategic Focus Set Stage for Breakthroughs in Ovarian Cancer Amid Industry Turbulence,

Published Thu, Apr 3 2025 12:55 PM UTC

In a significant strategic maneuver, Ernexa Therapeutics has successfully concluded a new funding round aimed at bolstering its endeavors in the realm of ovarian cancer treatment. This critical injection of capital arrives as the company unveils its rebranding efforts and fortifies its commitment to a revised strategic direction. The funds are anticipated to accelerate the p...
Management Changes

Eterna Therapeutics Faces Challenges Amid Leadership Changes and Financial Losses: Can New Vision Propel mRNA Innovation

Published Thu, Jan 9 2025 12:30 PM UTC

CAMBRIDGE, Mass.—In a bold move, Eterna Therapeutics Inc. recently announced the appointment of Dr. Elena Ratner, a world-renowned expert in obstetrics and gynecology from Yale University, to its Board of Directors. The company is aiming to leverage Dr. Ratner s extensive experience to enhance its ongoing research in ovarian cancer, a critical area of focus for the biotech...
Financing Agreement

Eterna Therapeutics Secures $9.2 Million Convertible Debt and Warrant Financing to Propel mRNA Cell Engineering Capabilities.

Published Thu, Dec 14 2023 11:56 PM UTC

Eterna Therapeutics: Secures $9.2 Million Funding for Advancing mRNA Cell Engineering
CAMBRIDGE, Mass., Dec. 14, 2023 - Eterna Therapeutics Inc. (Nasdaq: ERNA), a leading life science company focused on harnessing the potential of mRNA cell engineering to develop revolutionary new medications, recently disclosed the execution of a securities purchase agreement with accre...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 1.56
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.71
Working Capital Ratio 2.01
Leverage Ratio (MRQ) 0.97
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -17.79 $
Revenues (TTM) -
Cash Flow (TTM) 4.11 $
Cash 4.25 $
Book Value 2.7 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -2,451,600
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.